Literature DB >> 32386612

Pregnancy registry: three-year follow-up of children conceived from letrozole, clomiphene, or gonadotropins.

Richard S Legro1, Michael P Diamond2, Christos Coutifaris3, William D Schlaff4, Ruben Alvero4, Peter Casson5, Gregory M Christman6, R Mitchell Rosen7, Marcelle I Cedars7, Karl R Hansen8, Randal Robinson9, Valerie Baker10, Rebecca Usadi11, William C Dodson12, Stephanie J Estes12, Allen Kunselman13, Christina Stetter13, Kurt T Barnhart4, R Matthew Coward14, J C Trussell15, Stephen A Krawetz16, Nanette Santoro4, Hao Huang17, Heping Zhang17, Esther Eisenberg18.   

Abstract

OBJECTIVE: To study the development of children conceived from non-IVF infertility treatments consisting of gonadotropins, clomiphene, or letrozole.
DESIGN: Prospective cohort study.
SETTING: U.S. academic health centers. PATIENT(S): Children of women with polycystic ovary syndrome who conceived with letrozole (LTZ) or clomiphene (CC) in the PPCOS II study or women with unexplained infertility (AMIGOS study) who conceived with LTZ, CC, or gonadotropin (GN). INTERVENTION(S): Longitudinal annual follow-up from birth to age 3. MAIN OUTCOME MEASURE(S): Scores from Ages and Stages Developmental Questionnaire (ASQ), MacArthur-Bates Communicative Development Inventory (MCDI), and annual growth. RESULT(S): One hundred eighty-five children from 160 families participated in at least one follow-up evaluation from the two infertility trials. Most multiple gestations in the follow-up study resulted from GN treatment (n = 14) followed by CC (n = 6) and LTZ (n = 3). There were no significant differences among the three groups at any time point with respect to abnormal scores on the ASQ. On the MCDI Words and Gestures, the LTZ group scored significantly higher than the GN group for most items (phrases, early gestures, later gestures, and total gestures). Children in the CC group scored significantly higher than the GN group for the later gestures and total gestures items. CONCLUSION(S): Differences in growth and cognitive developmental rates among children conceived with first-line infertility therapies, including LTZ, are relatively minor and likely due to differences in multiple pregnancy rates.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Infertility; children; cognitive development; infant growth; ovulation induction

Mesh:

Substances:

Year:  2020        PMID: 32386612      PMCID: PMC7376442          DOI: 10.1016/j.fertnstert.2019.12.023

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  21 in total

1.  Utility of the MacArthur-Bates communicative development inventory in identifying language abilities of late-talking and typically developing toddlers.

Authors:  John Heilmann; Susan Ellis Weismer; Julia Evans; Christine Hollar
Journal:  Am J Speech Lang Pathol       Date:  2005-02       Impact factor: 2.408

Review 2.  Neuroactive steroids: focus on human brain.

Authors:  R C Melcangi; G Panzica; L M Garcia-Segura
Journal:  Neuroscience       Date:  2011-06-15       Impact factor: 3.590

3.  Assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial: baseline characteristics.

Authors:  Michael P Diamond; Richard S Legro; Christos Coutifaris; Ruben Alvero; Randal D Robinson; Peter Casson; Gregory M Christman; Joel Ager; Hao Huang; Karl R Hansen; Valerie Baker; Rebecca Usadi; Aimee Seungdamrong; G Wright Bates; R Mitchell Rosen; Daniel Haisonleder; Stephen A Krawetz; Kurt Barnhart; J C Trussell; Yufeng Jin; Nanette Santoro; Esther Eisenberg; Heping Zhang
Journal:  Fertil Steril       Date:  2015-02-20       Impact factor: 7.329

4.  Estimating rates of multiple gestation pregnancies: sample size calculation from the assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial.

Authors:  Michael P Diamond; Mohamed Mitwally; Robert Casper; Joel Ager; Richard S Legro; Robert Brzyski; Peter Casson; Esther Eisenberg; Heping Zhang
Journal:  Contemp Clin Trials       Date:  2011-07-20       Impact factor: 2.226

5.  Early delayed language development in very preterm infants: evidence from the MacArthur-Bates CDI.

Authors:  Susan Foster-Cohen; Jamie O Edgin; Patricia R Champion; Lianne J Woodward
Journal:  J Child Lang       Date:  2007-08

6.  Assisted reproductive technologies and children's neurodevelopmental outcomes.

Authors:  Mary L Hediger; Erin M Bell; Charlotte M Druschel; Germaine M Buck Louis
Journal:  Fertil Steril       Date:  2013-02       Impact factor: 7.329

7.  Improving the reporting of clinical trials of infertility treatments (IMPRINT): modifying the CONSORT statement†‡.

Authors:  Richard S Legro; Xiaoke Wu; Kurt T Barnhart; Cynthia Farquhar; Bart C J M Fauser; Ben Mol
Journal:  Hum Reprod       Date:  2014-09-12       Impact factor: 6.918

8.  Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens.

Authors:  A Morishima; M M Grumbach; E R Simpson; C Fisher; K Qin
Journal:  J Clin Endocrinol Metab       Date:  1995-12       Impact factor: 5.958

9.  Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo.

Authors:  Allison T Northen; Gwendolyn S Norman; Kristine Anderson; Lisa Moseley; Michelle Divito; Margaret Cotroneo; Melissa Swain; Sabine Bousleiman; Francee Johnson; Karen Dorman; Cynthia Milluzzi; Jo-Ann Tillinghast; Marcia Kerr; Gail Mallett; Elizabeth Thom; Susan Pagliaro; Garland D Anderson
Journal:  Obstet Gynecol       Date:  2007-10       Impact factor: 7.661

10.  Fertility treatment and risk of childhood and adolescent mental disorders: register based cohort study.

Authors:  Bjørn Bay; Erik Lykke Mortensen; Dorte Hvidtjørn; Ulrik Schiøler Kesmodel
Journal:  BMJ       Date:  2013-07-05
View more
  1 in total

1.  Effects of letrozole co-treatment on outcomes of gonadotropin-releasing hormone antagonist cycles in POSEIDON groups 3 and 4 expected poor responders.

Authors:  Alper Kahraman; Firat Tulek
Journal:  Arch Gynecol Obstet       Date:  2022-07-14       Impact factor: 2.493

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.